BACKGROUND Owing to the absence of specific symptoms in early-stage gastric cancer,most patients are diagnosed at intermediate or advanced stages.As a result,treatment often shifts from surgery to other therapies,with...
The authors thank all the patients and their families.We would like to acknowledge Dr.Yuchao Zhang from the Shanghai Institute of Nutrition and Health,Chinese Academy of Sciences for his suggestions in the analysis of the proteomics data of this study.This work is supported by the National Natural Science Foundation of China(no:82073293);the National Key R&D Program of China(no:2022YFC2503700);the State Key Project of Natural Science Foundation of China(no:81730097);Shanghai Top Priority Research Center Project(no.2023Zz02005);the Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center(Joint Project of Emerging Frontier Technology)(no.SHDC12018116);the Clinical Research Plan of Shanghai Hospital Development Center(no.SHDC2020CR1004A).
The majority of hepatocellular carcinoma(HCC)cases are diagnosed at an advanced stage.Currently,there are only a few therapeutic methods available for patients with advanced HCC and extrahepatic metastasis(EHM).System...
Background and aims:Conversion therapy downstages tumors and renders patients with unresectable hepatocel-lular carcinoma(HCC)eligible for radical resection.This study aimed to evaluate the efficacy and safety of tisl...